Johnson & Johnson has announced that it has applied to the U.S. Food and Drug Administration (FDA) to extend the indication for Prezcobix (darunavir/cobicistat) to allow treatment of HIV-1 in children aged at least 6 years and weighing at least 25 kg.

A parallel line extension application has also been submitted to the European Medicines Agency (EMA) for extended pediatric use in Europe, where the product is marketed under the name Rezolsta.

The laboratory reports that the new coformulated tablet (darunavir 675 mg/cobicistat 150 mg) has been developed to facilitate administration to young children. The new pediatric tablets are scored to facilitate swallowing.

If approved, this drug could provide healthcare providers with a new treatment option that ensures appropriate weight-based dosing to better meet the needs of young people living with HIV', said Penny Heaton, M.D., Global Director of Therapeutics, Infectious Diseases & Vaccines and Global Public Health R&D at Johnson & Johnson.

Copyright (c) 2024 CercleFinance.com. All rights reserved.